ZYBERNO
Stock Report
Updated Aug 31, 2026

UroGen Pharma Ltd. (URGN)

Healthcare • NASDAQ

$43.62

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
17.0/100
POOR BUSINESS
UroGen Pharma Ltd. (URGN) scores 17/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (0.0%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):CRITICAL (-35.3%)
Return on Capital (Capital Efficiency):CRITICAL (-291.5%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

UroGen Pharma Ltd. (URGN) stock report — Zyberno Score 17/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, URGN generated -$165.99M in Owner Earnings. Capital was deployed as follows: $299.00K invested in capital expenditures. Reinvestment rate: 0.0%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:43.62
Market Cap:$2.20B

Valuation Multiples (2)

P/S Ratio:11.64x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$2.35B

Price Action & Momentum (3)

Momentum Percentile:96 / 100
% of 52-Week High:85.8%
B. Profitability Assessment

Return Metrics (4)

ROA:-43.8%
Reinvestment Rate:0.0%
Fundamental Growth Rate (g):-0.1%

Margin Analysis (3)

Operating Margin Ttm:-35.3%
Net Margin Ttm:-51.7%
Ebitda Margin:-35.2%

TTM Performance (3)

Gross Margin Ttm:90.8%
Operating Margin Ttm:-35.3%
Net Margin Ttm:-51.7%

Yield Metrics (2)

Earnings Yield:-$11.37
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:76.0%
Latest Earnings Filed:2022-03-21

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):31.1%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:3.80x
Quick Ratio:3.41x
Cash Ratio:1.28x

Leverage Analysis (1)

Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:173,511,000.00
Cash And Cash Equivalents:79,133,000.00
Long Term Debt:$188.73M
Net Debt:$149.55M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $188.73M
Linear Growth: 31.1%
📊 Click to view full URGN Revenue analysis & methodology →
Cost Of Revenue Ttm:$17.28M

Profitability Breakdown (2)

Gross profit TTM: $171.46M
Linear Growth: 32.1%
📊 Click to view full URGN Gross Profit analysis & methodology →
-$66.65M

Bottom Line Performance (3)

-$97.64M
Income Before Tax:-$98.11M
Ebitda Ttm:-66,343,000.00

Operating Expenses (5)

Operating Expenses:0.00
R And D Expense:61,255,000.00
Sga Expense:176,854,000.00
Income Tax Expense:$935.00K
Interest Expense:0.00

Expense Ratios (3)

R And D To Revenue Percentage:84.5%
Sga To Revenue Percentage:244.1%
Ebitda Margin:-35.2%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$252.59M
Current Assets:$235.43M
Ppe Net:5,337,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:384,986,000.00
Current Liabilities:61,915,000.00
Long Term Debt:$188.73M
Short Term Debt:$39.95M

Equity & Capital (3)

Equity:-$132.40M
Retained Earnings:-$997.64M
Common Stock:100,000,000.00

Working Capital Items (3)

Accounts Receivable:88,757,000.00
Inventory:24,589,000.00
Accounts Payable:15,472,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:5,331,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$165.74M-$166.04M

Investment Activities (2)

Investing Cash Flow:-$20.69M
Capital Expenditures Ttm:299,000.00

Financing Activities (3)

Financing Cash Flow:$65.20M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$65.35M
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:310,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-1.97
-$4.96
Earnings Per Share Ttm:-$1.94

Revenue & Cash Per Share (2)

Sales Per Share Ttm:3.75
Operating Cash Flow Per Share:-$3.22

Book Value & Capital (2)

Book Value Per Share:-$2.63
Cash Per Share:1.57

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.85x
Working Capital Turnover Ttm:1.09x

Receivables Management (2)

Receivables Turnover Ttm:2.13x
Days Sales Outstanding Ttm:171.65

Inventory Management (2)

Inventory Turnover Ttm:0.70x
Days Inventory Outstanding Ttm:519.45

Payables & Cash Cycle (2)

Days Payable Outstanding:326.85
Cash Conversion Cycle:364.25
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:40.00
Quality Score:25.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$165.99M

Damodaran Growth Analysis (2)

Reinvestment Rate:0.0%
Fundamental Growth Rate (g):-0.1%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):31.1%

Other Growth Rates (1)

Gross Profit Growth Rate (Linear):32.1%
C. Company Profile & Context

Corporate Information (6)

Symbol:URGN
Company Name:UroGen Pharma Ltd.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:Israel

Market Classification (3)

Market Cap Category:N/A
Price Category:medium
Volume Category:N/A

Share Structure (3)

Shares Outstanding:50.38M
Shares Outstanding Basic:50.38M
Shares Outstanding Diluted:0

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-31 18:43:29 UTC
Data Timestamp:2026-08-31T18:43:29.611883
Scroll to Top